Sinopharm Leads $20 Million Investment in Singapore’s Novena; Plans Joint $150 Million Healthcare Fund

Sinopharm
Published on: June 25, 2019
Author: Amy Liu

Novena Global Lifecare, a Singapore company with 250 aesthetic clinics and sales outlets in southeast Asia, will receive an investment of up to $20 million from Sinopharm Capital and Cedarlake Capital. Founded in 2010, Novena is one of the largest medical healthcare and aesthetic groups in the region. In addition, the three companies plan to raise as much as $150 million for a new Sino-Singapore Healthcare Fund. The fund will invest in southeast Asian medical services, biomedical projects, mature drugs and precision medical drugs.

Source: China Biotoday

Biotechnology Healthcare Services Life Science Pharmaceutical